Research output per year
Research output per year
Personal profile
Biography
Emile Voest is professor of Medical Oncology, senior group leader at the Netherlands Cancer Institute, senior scientist of the Oncode Institute, and translational scientist. He is the current chair of the board of directors of Cancer Core Europe, a collaboration of 7 excellent comprehensive cancer centers. Until 2021, he served as executive medical director of the Netherlands Cancer Institute. He is also an independent, non-executive board member of Sanofi, is co-founder and serves on the non-executive board of the Hartwig Medical Foundation. He recently has co-founded Mosaic Therapeutics, devoted to developing new combinatorial treatments in a specific genomic background.
His academic group is devoted to bringing precision medicine to patients and is focused on large scale genomic sequencing of patients with metastatic cancer, the development of co-culture models of primary cultures of tumors (i.c. organoids) and immune cells to improve drug development and immunotherapy and to determine which treatment is best for a specific patient via computational, integrated approaches.
Personal webpage
Side activities
1999- Professor of Medical Oncology, University of Utrecht, University Medical Center, Utrecht (UP)
2013- Editorial board of Clinical Cancer Research (UP)
2015- Editorial board of JAMA Oncology (UP)
2015- Consultant Biogeneration Ventures (PtP)
2015- Co-founder and member of supervisory board Hartwig Medical Foundation (UP)
2016- Editorial board ESMO Open, Cancer Horizons (UP)
2019- Senior Group Leader of the Oncode Institute (UP)
2020- Co-founder and Strategic Advisor Mosaic Therapeutics (founded July, 2020), Cambridge, UK (PtP)
2020- Global Clinical Advisory Board Cambridge Cancer Center, UK (UP)
2021- Scientific Advisory Board Institute Gustave Roussy, Paris, France (UP)
2021- Scientific Advisory Board GROW Oncology, Maastricht, Netherlands (UP)
2022- Independent, non-executive board member Sanofi, Paris, France (PtP)
2022- Board member Center for Personalized Cancer Treatment (UP)
UP=unpaid
PtP= paid to person
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)
Verkerk, K., Zeverijn, L. J., van de Haar, J., Roepman, P., Geurts, B. S., Spiekman, A. C., van der Noort, V., van Berge Henegouwen, J. M., Hoes, L. R., van der Wijngaart, H., Jansen, A. M. L., de Leng, W. W. J., Gelderblom, A. J., Verheul, H. M. W. & Voest, E. E., Jan 2025, In: ESMO open. 10, 1, 104112.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Downloads (Pure) -
A pan-cancer analysis of the microbiome in metastatic cancer
Battaglia, T. W., Mimpen, I. L., Traets, J. J. H., van Hoeck, A., Zeverijn, L. J., Geurts, B. S., de Wit, G. F., Noë, M., Hofland, I., Vos, J. L., Cornelissen, S., Alkemade, M., Broeks, A., Zuur, C. L., Cuppen, E., Wessels, L., van de Haar, J. & Voest, E., 25 Apr 2024, In: Cell. 187, 9, p. 2324-2335.e19Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Downloads (Pure) -
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy
Geurts, B. S., Zeverijn, L. J., van Berge Henegouwen, J. M., van der Wijngaart, H., Hoes, L. R., de Wit, G. F., Spiekman, I. A., Battaglia, T. W., van Beek, D. M., Roepman, P., Jansen, A. M., de Leng, W. W., Broeks, A., Labots, M., van Herpen, C. M., Gelderblom, H., Verheul, H. M., Snaebjornsson, P. & Voest, E. E., Jul 2024, In: Journal of Pathology. 263, 3, p. 288-299 12 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer
Van De Haar, J., Mankor, J. M., Hummelink, K., Monkhorst, K., Smit, E. F., Wessels, L. F. A., Cuppen, E., Aerts, J. G. J. V. & Voest, E. E., 1 Apr 2024, In: Clinical Cancer Research. 30, 7, p. 1307-1318 12 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile2 Downloads (Pure) -
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol
Spiekman, I. A. C., Geurts, B. S., Zeverijn, L. J., de Wit, G. F., van der Noort, V., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., Kusters, B., Beerepoot, L. V., de Vos, F. Y. F. L., de Groot, D.-J. A., de Groot, J. W. B., Hoeben, A., Buter, J., Gelderblom, H. A. J., Voest, E. E. & Verheul, H. M. W., 3 May 2024, In: The oncologist. 29, 5, p. 431-440 10 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile